• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2017     HAYES, Inc. Subcutaneous implantable cardioverter defibrillator (S-ICD) for prevention of sudden cardiac death
2017     Health Quality Ontario (HQO) Fibreglass total contact casting, removable cast walkers, and irremovable cast walkers to treat diabetic neuropathic foot ulcers: OHTAC recommendation
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for secondary malignant neoplasms of the liver and the intrahepatic bile ducts - Addendum to commission H16-02E]
2017     HAYES, Inc. clonoSEQ (Adaptive Biotechnologies)
2017     Health Quality Ontario (HQO) Retinal prosthesis system for advanced retinitis pigmentosa: OHTAC Recommendation
2017     HAYES, Inc. GeneSight Psychotropic (Assurex Health Inc.)
2017     Health Quality Ontario (HQO) Electrical stimulation for pressure injuries: OHTAC recommendation
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl peptidase-4 inhibitors as treatment for diabetes mellitus]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inotuzumab ozogamicin (acute lymphocytic leukaemia) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2017     NIHR Health Services and Delivery Research programme SUPPORT-HF 2 (Seamless User-centred Proactive Provision Of Risk-stratified Treatment for Heart Failure) - An internal pilot phase of a planned large-scale randomised trial of an integrated, technology-enabled care delivery model
2017     HAYES, Inc. Prometheus IBD sgi Diagnostic (Prometheus Laboratories Inc.)
2017     Health Quality Ontario (HQO) Psychotherapy for major depressive disorder and generalized anxiety disorder: OHTAC recommendation
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Thiazolidinediones for the treatment of type 2 diabetes mellitus]
2017     NIHR Health Technology Assessment programme Debt Counselling for Depression in Primary Care: an adaptive randomised controlled pilot trial (DeCoDer study)
2017     NIHR Health Services and Delivery Research programme Can Health-care Assistant Training improve the relational care of older people? (CHAT) A development and feasibility study of a complex intervention
2017     Health Quality Ontario (HQO) Home-based subcutaneous infusion of immunoglobulin for primary and secondary immunodeficiencies: OHTAC recommendation
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Preoperative virtual planning assisted surgery]
2017     NIHR Health Services and Delivery Research programme A mixed-methods study exploring the characteristics and needs of long stay patients in high and medium secure settings in England: implications for service organisation
2017     NIHR Health Technology Assessment programme A Very Early Rehabilitation Trial after stroke (AVERT): a Phase III, multicentre, randomised controlled trial
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Posaconazole for invasive fungal infection treatment and prevention in neutropenic patients]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Services and Delivery Research programme Updated meta-review of evidence on support for carers
2017     NIHR Health Technology Assessment programme Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Bilateral cochlear implants in hearing loss]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C) - Benefit assessment according to § 35a Social Code Book V]
2017     NIHR Health Services and Delivery Research programme REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care
2017     NIHR Health Technology Assessment programme Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in fractures and bone pseudoarthrosis]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Services and Delivery Research programme Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study
2017     NIHR Health Technology Assessment programme International multicentre randomised controlled trial of improvisational music therapy for children with autism spectrum disorder: TIME-A study
2017     European Network for Health Technology Assessment (EUnetHTA) Antibacterial-coated sutures versus non-antibacterial-coated sutures for the prevention of abdominal, superficial and deep incisional, surgical site infection (SSI)
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Efavirenz, Emtricitabine and Tenofovir (Simplir®) in HIV infection – comparison with other brands in Argentina]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24]
2017     NIHR Health Services and Delivery Research programme Incentives in Diabetic Eye Assessment by Screening (IDEAS) trial: a three-armed randomised controlled trial of financial incentives
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Alprostadil for nonrevascularizable critical lower limb ischemia]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to A-17-24]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions to improve foster children's mental and physical health]
2017     NIHR Public Health Research (PHR) programme Increasing boys' and girls' intention to avoid teenage pregnancy: a cluster randomised control feasibility trial of an interactive video drama based intervention in post-primary schools in Northern Ireland
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Atazanavir/cobicistat (Evotaz®) in HIV infection]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Addendum]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Methods to increase chronically ill patients' participation in health care and services]
2017     NIHR Health Technology Assessment programme Cognitive behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Functioning and disability - an evidence map]
2017     European Network for Health Technology Assessment (EUnetHTA) Repetitive transcranial magnetic stimulation for treatment-resistant major depression
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Deferred parathyroid autograft with cryopreserved tissue for the surgical management of hyperparathyroidism]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for biomarker tests in breast cancer - Addendum to Commission D14-01]
2017     NIHR Health Technology Assessment programme A novel peer-support intervention using motivational interviewing for breastfeeding maintenance:a UK feasibility study
2017     NIHR Health Technology Assessment programme Prehospital randomised assessment of a mechanical compression device in out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised trial and economic evaluation
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dolutegravir, Abacavir and Lamivudine (Triumeq®) in HIV infection]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Pre-conception care for women with type 1 or type 2 diabetes: a mixed methods study exploring uptake of pre-conception care
2017     Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) [Trancatheter ablation with cryoballoon for the treatment of atrial fibrillation. A rapid assessment]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab biosimilars]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Nintedanib (Ofev®) in the treatment of idiopathic pulmonary fibrosis]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Matrix-assisted laser desorption/ionization-time of flight analyzer (MALDI-TOF) in infections]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Home-based health promotion for older people with mild frailty: the HomeHealth intervention development and feasibility RCT
2017     NIHR Health Technology Assessment programme Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Single-donor platelet concentrate in patients with thrombocytopenia]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Public Health Research (PHR) programme Steps Towards Alcohol Misuse Prevention Programme (STAMPP): a school- and community-based cluster randomised controlled trial
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Peritoneal dialysis versus hemodialysis for end stage renal disease]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brodalumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Cerebrospinal fluid neurotransmitter screening in encephalopathies]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis type IVA) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (new scientific findings)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Vemurafenib in combination with Cobimetinib for advanced melanoma]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Health Sciences Institute in Aragon (IACS) Motorised assistive walking device in patients with muscle weakness in the lower limbs
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Pelvic vein embolization or sclerotherapy in pelvic congestion syndrome]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Analysis of clinical studies of medical devices]
2017     NIHR Health Technology Assessment programme A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Hyperbaric oxygen therapy for chronic ulcers]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2017     NIHR Health Technology Assessment programme The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Intravesical hyaluronic acid in interstitial cystitis/painful bladder syndrome]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Uncertainty in the efficiency frontiers]
2017     NIHR Health Technology Assessment programme Observational study to estimate the changes in the effectiveness of bacillus Calmette Guerin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK
2017     NIHR Health Technology Assessment programme Managing Faecal INcontinence in people with advanced dementia resident in Care Homes (FINCH) study: a realist synthesis of the evidence
2017     NIHR Health Technology Assessment programme Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Trabecular bone score-TBS for bone fragility diagnosis]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Antibodies to pgp9.5 in small fiber neuropathy]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Assessing the performance of methodological search filters to improve the efficiency of evidence information retrieval: five literature reviews and a qualitative study
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketoanalogue diet for advanced chronic kidney failure]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial
2017     NIHR Health Technology Assessment programme Facet-joint injections for non-specific low back pain: a feasibility RCT
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Biologics in patients with spondyloarthritis]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of a multifaceted podiatry intervention for falls prevention in older people: a multicentre cohort randomised controlled trial (the REducing Falls with ORthoses and a Multifaceted podiatry intervention trial)